Document is current
Any future updates will be listed below
-
Authors
Orchard, Kim https://orcid.org/0000-0003-2276-3925
Langford, Jonathan
Guy, Matthew https://orcid.org/0000-0002-6818-2010
Lewis, Gemma
Michopoulou, Sofia
Cooper, Margaret
Zvavamwe, Clint
Richardson, Deborah
Lewington, Valerie
- License Information
-
More Information
Article History
Received: 2 February 2024
Revised: 14 May 2024
Accepted: 17 May 2024
First Online: 12 June 2024
Competing interests
: KO has contributed to advisory boards for Gilead, Janssen, Takeda and on consultancy basis for Telix Pharmaceuticals. KO has IP in the targeted radiotherapy technology. JL has been employed on a consultancy basis by Telix Pharmaceuticals. VL has contributed to advisory boards for Immedica Pharma AG. The other authors have declared no conflicts of interest. The radiolabelled anti-CD66 technology was acquired by Telix Pharmaceuticals in 2020. All the work described in this report was completed before acquisition by Telix.
